ImmunoGenex to hold medical lecture series for English-speaking public in Tokyo

ImmunoGenex will be launching in December a medical lecture series for the general English-speaking public, with a focus on precision medicine and cancer immunotherapy in Japan.

With 2.5 million foreigners living in Japan, there is a great lack of information regarding what is available to this community in early diagnosis and personalized medicine. Whether a personal cancer scare, a family history of cancer, a loved one, friend or colleague who is affected; cancer is pervasive. And yet the tools available to determine our cancer risks, early detection, monitoring and treatments, particularly immunotherapeutic interventions are largely unknown.

ImmunoGenex is at the forefront of personalized medicine and cancer immunotherapy, and what it has to offer is unique to Japan and unavailable in the U.S., Europe or elsewhere in the world. 

Event details

Medical lecture series: “Latest developments in Early Cancer Detection and Immunotherapy” (*Plus Networking event)

Date/time: Dec 6. Lecture from 6 p.m.-7 p.m. Networking event 7 p.m. - 7:30 p.m. (light refreshments will be served)

Venue: Roppongi Symphony Salon 8F, C’Bon View Bldg (across from Roppongi Hills), 7-18-12 Roppongi Minato-ku Tokyo

Speaker: Minako Abe, MD – CEO, ImmunoGenex

Entrance fee: Free (maximum 40 participants)

Advance registration: please sign up by emailing info@lsri.co.jp

About ImmunoGenex

ImmunoGenex is a leading-edge biotechnology company committed to providing an accurate picture of one’s health and risk factors by looking at genetics and epigenetics to help direct individualized medical treatments for cancer and other illnesses. It offers innovative biomedical testing through liquid biopsies to support personalized medicine and cancer immunotherapy.

Tests include genetic and epigenetic testing, expression profiling, Cell-free DNA (cfDNA), Circulating tumor cells (CTC), Cytokine Assays, and Genetic Health Risk Reports.

The company also provides expertise and technology to create biological therapies including individualized Dendritic Cell cancer vaccines and Natural Killer cell therapies, at the direction of and within the licensed cell processing facility of the Fukuro Clinic.